The Impact Of GLP-1s On Cardiovascular Clinical Development

GLP-1 receptor agonists are reshaping expectations for cardiometabolic care, creating new opportunities—and new challenges—for clinical development. Beyond their established role in weight management and diabetes, these therapies are demonstrating meaningful cardiovascular benefits that are influencing study design, endpoint selection, patient recruitment strategies, and regulatory considerations. As the therapeutic landscape evolves, sponsors must navigate increasingly complex trial requirements while identifying the right patient populations and generating robust evidence to support differentiation.

This session explores the growing impact of GLP-1 therapies on cardiovascular research, highlighting key trends in clinical development and the factors driving continued investment in the field. Insights into operational considerations, emerging indications, and the future direction of cardiovascular outcomes research provide valuable context for organizations advancing next-generation therapies. Watch the webinar to gain a clearer understanding of how GLP-1 innovations are influencing the future of cardiovascular drug development.